Sentences with phrase «zinc prices at»

With first assay results imminent and zinc prices at 10 - year highs, investors will be watching closely with a view to familiarising themselves with one of the world's great forgotten mining treasures.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Despite the recent pullback in prices, zinc is still trading hands at multi-year highs.

Net debt excluding zinc metal prepay and perpetual securities of EUR 1.351 billion at the end of Q1 2018, an increase of EUR 249 million on 31 December 2017 driven predominantly by working capital outflow mainly due to higher commodity prices and amortisation of prepays.

Daily News Wednesday, December 31, 2008 Juniors looking for a lifeline With commodities prices at multi-year lows, nickel and zinc mines closing, and exploration programs being scaled back or even cancelled, anxiety is mounting at all levels of the mining and exploration industries.

It seems unlikely that ZINC would be able to generate high returns ex-ante in a commodity industry, especially when the commodity price isn't at the top of its cycle.

At the time before they filed for bankruptcy, management could legitimately say to themselves, «If the price of zinc remains this low we will shortly be insolvent, particularly if our new processing plant doesn't work out.»

At a great price (under $ 30), the Leatherberg is constructed from real cowhide leather with a zinc - alloy snap hook, and comes with a full one - year warranty for any reason.

The price participation commences above a zinc price of $ 2,100 per tonne and is applicable at set zinc prices.